KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Preferred Stock Liabilities (2016 - 2017)

Historic Preferred Stock Liabilities for Moderna (MRNA) over the last 2 years, with Q4 2017 value amounting to $1.2 billion.

  • Moderna's Preferred Stock Liabilities changed 0.0% to $1.2 billion in Q4 2017 from the same period last year, while for Dec 2017 it was $1.2 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.2 billion for FY2017, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2017, Moderna's Preferred Stock Liabilities is $1.2 billion, which was down 0.0% from $1.2 billion recorded in Q4 2016.
  • Moderna's Preferred Stock Liabilities' 5-year high stood at $1.2 billion during Q4 2016, with a 5-year trough of $1.2 billion in Q4 2016.